Mayne Pharma revenues soar

 In Australia, NewZealand, Pharmacy
Mayne Pharma has posted $45 million in revenues in the first four months of fiscal 2014, indicating full year revenues are running at $135 million.
Revenues in the first four months are up 230 per cent, shareholders were told at today’s annual general meeting, boosted by the acquisition earlier of US company Metrics along with a lift in sales of its in-house developed drug Doryx.  Sydney Morning Herald – Read more…

Recent Posts

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.